NICE to Charge up to $282,000 for New Drug Assessments

The UK’s National Institute of Health and Care Excellence (NICE) plans to start charging pharmaceutical companies new fees for each cost-effectiveness assessment for a new medicine beginning next year. The new fees could be up to $282,000! Find out more here. (Source: Zachary Brennan, RAPS, 10/3/16)

You might also be interested in:

CVS Caremark's Foray into Cost-Effectiveness Analysis Raises… September 25, 2018
CVS Health Execs Respond to NPC's Criticism of New Program September 18, 2018
ICER Using New Economic Modeling Platform for Value Assessment August 24, 2018
PhRMA Foundation to Fund New Centers of Excellence February 11, 2019
Opinions Divided on CVS Program September 19, 2018
ICER Recommends Major Price Drop for Spinraza April 4, 2019
Pharmacy Benefit Managers: A Mechanism for Containing Costs or… October 1, 2018